Generation Bio Co

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle, or ctLNP platform. ctLNP delivery system is designed to address the limitations of existing technologies and comprises three elements. First, LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen. Second, identify and refine a small format targeting ligand against a receptor uniquely expressed on the target cell to achieve highly potent and selective delivery to specific tissues and cell types of interest. Finally, bioconjugated linkers that facilitate modular attachment of the targeting ligands to the core stealth LNP; and novel immune-quiet DNA (iqDNA) enable long-lasting high levels of gene expression from non-integrating episomes and avoid innate immune sensors that have long prevented DNA from use in non-viral systems. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.